Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest update is out from Trevi Therapeutics ( (TRVI) ).
Trevi Therapeutics, a biopharmaceutical company focused on chronic cough treatments, has announced key executive changes with James Cassella joining as Chief Development Officer and David Clark stepping down as Chief Medical Officer but continuing as a consultant. The company’s investigational therapy, Haduvio, aims to address unmet medical needs in chronic cough conditions and is advancing towards pivotal development and potential regulatory submission. Cassella’s extensive experience in CNS drug development is expected to significantly contribute to Haduvio’s progress.
For a thorough assessment of TRVI stock, go to TipRanks’ Stock Analysis page.